Viking Therapeutics has delivered very strong long term share returns, and that kind of history can leave investors wondering whether the current US$28.44 price still lines up with what its balance sheet says the business is worth. With the spotlight on Viking Therapeutics as it pushes ahead in obesity drug development, the open question is how far the market price has moved relative to its book value. Over the past 5 years, Viking Therapeutics has returned about 391.2%, which raises the...
These drugmakers offer very different risk-reward profiles.
Viking aims to enter the weight loss drug market.
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Detailed price information for Viking Thera (VKTX-Q) from The Globe and Mail including charting and trades.
Moby summary of Viking Therapeutics, Inc.'s Q3 2026 earnings call
Viking Therapeutics faces dilution risk, rising costs, and tough obesity drug competition. Read here for a detailed analysis of VKTX stock.
BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials.
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines.
Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.
This is the newest page. Registered accounts read further back.